DALLAS — Judith S. Hochman, M.D., FAHA, senior associate dean for clinical sciences and founding director of the Cardiovascular Clinical Research Center at NYU Grossman School of Medicine, will receive the 2025 Research Achievement Award at the American Heart Association’s Scientific Sessions 2025. The meeting, scheduled for Nov. 7-10 in New Orleans, is a premier global exchange of the latest scientific advancements in cardiovascular science. Dr. Hochman will be presented with the award during the opening session on Sunday, Nov. 9.
Dr. Hochman, who also serves as founding co-director of NYU Langone Health’s Clinical and Translational Science Institute (CTSI) and Harold Snyder Family Professor of Cardiology, has been principal investigator and study chair for several pivotal National Heart, Lung, and Blood Institute (NHLBI)-funded international trials. These trials have directly influenced global clinical practice guidelines in cardiology.
“It’s my privilege to present Dr. Judith Hochman with the 2025 Research Achievement Award,” said Stacey E. Rosen, M.D., FAHA, the American Heart Association’s 2025-2026 volunteer president. “Her research has directly impacted patient care across the full spectrum of ischemic heart disease. She is a visionary leader, unafraid to tackle complex questions, and her relentless commitment to improving patient outcomes has been a driving force in numerous cardiology advances available today.”
Dr. Hochman led the Occluded Artery Trial (OAT), which demonstrated no clinical benefit for late angioplasty in stable post-myocardial infarction (MI) patients despite promising animal model findings. The SHOCK Trial established a clear survival advantage for early revascularization in patients with cardiogenic shock due to left ventricular failure after acute MI, reducing mortality by 13 absolute percentage points at one year. Her most recent trial, the NHLBI-funded ISCHEMIA trial, compared initial invasive versus conservative treatment strategies for stable coronary artery disease. It found no significant difference in all-cause mortality but identified substantial quality-of-life improvement among patients with angina who received invasive treatment.
These three trials led to new or revised recommendations regarding revascularization in joint clinical guidelines from the American Heart Association/American College of Cardiology and other international medical organizations. Dr. Hochman’s scientific findings and her role on multiple guideline writing committees have been instrumental in shaping clinical practice.
Dr. Hochman is also recognized as a trailblazer in women’s cardiovascular health. In the TIMI IIIb trial, she was among the first to study sex differences in women with acute coronary syndromes and to recognize the substantial incidence of women with these syndromes having no obstructive coronary disease. Her leadership on the National Institutes of Health’s Women’s Health Initiative Advisory Committee reflects her enduring commitment to advancing women’s health.
“It’s a true honor to be recognized by the American Heart Association,” said Dr. Hochman. “I have been fortunate to collaborate with an extraordinary community of investigators, and together, we have contributed to evidence-based care. My passion has always been improving outcomes for patients through rigorous science.”
Dr. Hochman’s decades-long commitment to the Heart Association includes service on the Science Advisory Coordinating Committee, the Scientific Sessions Planning Committee, and the Women in Cardiology Committee. She has previously received the American Heart Association Distinguished Scientist Award in 2023, the James B. Herrick Award in 2018, the 2014 Clinical Research Prize, and the Women in Cardiology Mentoring Award in 2008.
Dr. Hochman earned her medical degree from Harvard Medical School and a master’s degree in cellular and developmental biology, also at Harvard. She completed her residency at Brigham and Women’s Hospital and a cardiology fellowship at Johns Hopkins University School of Medicine. She has authored more than 500 peer-reviewed publications and serves on editorial boards for Circulation, JAMA Cardiology, and the European Heart Journal.
